BLOOD VESSELS IN COLORECTAL TUMOR MODEL-RESPONSE TO ANGIOGENIC THERAPIES

结直肠肿瘤模型中的血管对血管生成治疗的反应

• 批准号: 8171619
• 负责人: ERGYS SUBASHI
• 金额: $ 1.09万
• 依托单位: DUKE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2010
• 资助国家: 美国
• 起止时间: 2010-07-01 至 2011-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8171619
• 关键词: Anesthetics; Angiography; Animals; Avastin; Blood; Blood Vessels; Blood Volume; Blood flow; Carotid Arteries; Colorectal Neoplasms; Complement; Computer Retrieval of Information on Scientific Projects Database; Contrast Media; Custom; Development; Digital Subtraction Angiography; Dose; Formalin; Funding; Gadolinium; Gadopentetate Dimeglumine; Grant; Histology; Human Cell Line; Image; Implant; Institution; Liposomes; Magnetic Resonance Angiography; Magnetic Resonance Imaging; Measurement; Measures; Modality; Modeling; Mus; Neck; Overdose; Pathway interactions; Pharmaceutical Preparations; Research; Research Personnel; Resolution; Resources; Roentgen Rays; Scanning; Signal Transduction; Source; Surface; Tail; Techniques; Time; United States National Institutes of Health; Veins; Venous; base; density; femoral artery; in vivo; interest; response; tumor; uptake

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The purpose of this project is to study the development of blood vessels in a colorectal tumor model and the response to anti-angiogenic therapies. Tumors from a human cell line will be implanted on the flank of mice and will be imaged with two different modalities: x-ray and MRI. The x-ray based technique will be digital subtraction angiography (DSA) while the MR-based techniques will be dynamic contrast enhanced (DCE) MRI and angiography. Avastin and Irinitecan are potential drugs that will be utilized in this project. The density, number of vessels, and tortuosity will be studied as a function of tumor size and drug dose. 1) In-vivo MRI (141B Bryan). High resolution MR angiography will be used to study the anatomical distribution of blood vessels in the tumor. DCE-MRI will complement the anatomical measurements with functional information by quantifying the transfer rate of contrast from intravascular to extravascular space which is a measure of vessel leakiness. A custom build surface coil will be used for signal reception. The contrast agents employed in these scans will be Magnevist and blood-pool liposomal gadolinium. Imaging time for MR scans will be approximately 45 minutes. 2) In-vivo X-ray (131 Bryan). DSA imaging provides fast acquisition options not easily achieved with MR that enables the study of contrast uptake and/or clearance at heartbeat resolution. Arterial supply can be distinguished from venous pathways through the analysis of time density curves (TDC). TDCs are also used to measure the mean transit time, blood flow, and blood volume in a region of interest. Isovue250 will be injected in the tail vein and/or femoral artery (or carotid artery if the tumors are implanted in the neck). Imaging time for DSA scans will be approximately 20 minutes. 3) At the completion of the imaging studies, animals will be sacrificed by anesthetic overdose and tumors will be excised and fixed in formalin or Bouin's for conventional histology.

该子项目是利用该技术的众多研究子项目之一 资源由 NIH/NCRR 资助的中心拨款提供。子项目和 研究者 (PI) 可能已从 NIH 的另一个来源获得主要资金， 因此可以在其他 CRISP 条目中表示。列出的机构是 对于中心来说，它不一定是研究者的机构。 该项目的目的是研究结直肠肿瘤模型中血管的发育以及抗血管生成疗法的反应。来自人类细胞系的肿瘤将被植入小鼠的侧腹，并通过两种不同的方式进行成像：X 射线和 MRI。基于 X 射线的技术将是数字减影血管造影 (DSA)，而基于 MR 的技术将是动态对比增强 (DCE) MRI 和血管造影。阿瓦斯汀和伊立替康是该项目中将使用的潜在药物。将研究密度、血管数量和弯曲度作为肿瘤大小和药物剂量的函数。 1) 体内 MRI (141B 布莱恩)。高分辨率磁共振血管造影将用于研究肿瘤中血管的解剖分布。 DCE-MRI 将通过量化造影剂从血管内到血管外空间的传输率（血管渗漏的衡量标准）来补充功能信息的解剖测量。定制的表面线圈将用于信号接收。这些扫描中使用的造影剂是 Magnevist 和血池脂质体钆。 MR 扫描的成像时间约为 45 分钟。 2) 体内 X 射线 (131 Bryan)。 DSA 成像提供了 MR 不易实现的快速采集选项，能够以心跳分辨率研究造影剂摄取和/或清除。通过时间密度曲线（TDC）分析可以区分动脉供应和静脉通路。 TDC 还用于测量感兴趣区域的平均通过时间、血流量和血容量。 Isovue250 将注射到尾静脉和/或股动脉（如果肿瘤植入颈部，则注射到颈动脉）。 DSA 扫描的成像时间约为 20 分钟。 3)完成成像研究后，通过过量麻醉处死动物，切除肿瘤并固定在福尔马林或Bouin's中用于常规组织学。